ONK Therapeutics and NAYA Biosciences to assess proof-of-concept and establish activity and feasibility of the combination of ONK™s optimally engineered natural killer (NK) cell therapies and NAYA™s...
The European Patent Office (EPO) has granted WEHI a patent for CISH knockout (KO) in Natural Killer (NK) cells which is exclusively licensed to ONK Therapeutics for cell immunotherapy purposes, giving...
Bruce McCreedy Ph.D. joins the Executive Leadership Team as Chief Scientific Officer, as the company continues to grow its US-based operationsBrings three decades of experience in drug development,...
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced the first in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy.
GALWAY, Ireland and SAN DIEGO, March 23, 2022 /PRNewswire/ -- ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced that it has appointed Allan Reine as independent Non-Executive Director to its Board.
Intellia is on a deal spree. The first-in-human gene editing biotech will receive up to $920 million from ONK Therapeutics in a collaboration agreement focused on CRISPR-edited natural killer cell therapies.
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics, an innovative NK cell therapy platform company, today announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.